Quick answer
What is multiple sclerosis?
Multiple sclerosis is an autoimmune condition where the immune system attacks the myelin coating of nerves in the brain and spinal cord — causing vision problems, numbness, weakness, balance issues, and fatigue in episodes or progressively. Most common neurological disease in young adults — diagnosis typically 20s to 40s. MRI and neurology assessment confirm. Disease-modifying drugs reduce relapses — no cure yet but outcomes improving. See a GP urgently for sudden vision loss in one eye or new neurological symptoms lasting over 24 hours.
Multiple sclerosis — immune attack on myelin
Multiple sclerosis (MS) is chronic autoimmune demyelination of central nervous system (brain + spinal cord) — disrupted nerve conduction → variable neurological symptoms.
Most common disabling neurological disease of young adults — UK ~130,000.
Peak onset 20s–40s — not childhood rare, diagnosis later life possible.
How MS presents
Relapsing-remitting pattern:
- new symptoms over days
- plateau then partial recovery over weeks–months
- attacks separated in time, ** lesions separated in space**
Common symptoms:
- optic neuritis — painful monocular vision loss
- sensory — numbness, pins and needles, band-like torso
- motor — weakness, spasticity
- coordination — ataxia, tremor
- brainstem — diplopia, facial weakness
- fatigue — most disabling symptom many
- bladder/bowel — urgency, retention
- cognitive — processing speed
Progressive forms:
- SPMS — gradual decline after RRMS
- PPMS — progression from onset — 10–15%
Diagnosis
McDonald criteria — MRI + clinical
MRI brain/spine:
- periventricular, juxtacortical, infratentorial, spinal T2/FLAIR lesions
- ** Dawson fingers**
- gadolinium enhancement — active inflammation
LP — oligoclonal bands — supportive
Exclude mimics:
- NMOSD — aquaporin-4 antibody
- MOGAD
- SLE, Sjögren, sarcoid
- vitamin B12 deficiency
Treatment
Relapse
High-dose IV methylprednisolone — 3–5 days — speeds recovery, doesn’t alter long-term disability
Disease-modifying therapies (DMTs)
Reduce relapse rate, MRI activity, disability progression:
| Efficacy tier | Examples |
|---|---|
| Moderate | dimethyl fumarate, teriflunomide, fingolimod |
| High | ocrelizumab, natalizumab, alemtuzumab, cladribine |
Choice — activity, prognosis, family planning, JCV status (PML risk with natalizumab)
PPMS
Ocrelizumab — only licensed DMT with PPMS evidence
Symptoms
- fatigue — exercise, modafinil selected
- spasticity — baclofen
- neuropathic pain — gabapentin
- bladder — oxybutynin, intermittent self-catheterisation
Living with MS
MS Society — support, benefits advice
Heat sensitivity — Uhthoff — cooling strategies
Vitamin D — maintain sufficiency
Smoking cessation — accelerates progression
Pregnancy — often reduced relapse third trimester, rebound postpartum — plan with neurologist
MS is unpredictable not untreatable — early neurology, DMT, symptom management preserve life trajectory.
Common questions
- What are the first signs of MS?
- Optic neuritis — blurred or painful vision one eye; numbness or tingling limbs or face; weakness; balance problems; Lhermitte sign — electric shock down spine on neck flexion; fatigue; bladder urgency. Symptoms often develop over days, last weeks, then improve partially — disseminated in time and space.
- What causes multiple sclerosis?
- Autoimmune demyelination — exact trigger unknown — combination of genetic susceptibility and environmental factors (low vitamin D, EBV infection, smoking). Not contagious. More common further from equator — latitude gradient in incidence.
- Is there a cure for MS?
- No cure currently — disease-modifying treatments reduce relapses and slow progression especially relapsing forms. Stem cell transplantation (HSCT) for highly active MS in specialist centres. Symptomatic treatments — fatigue management, spasticity drugs, bladder care. Research active globally.
- What is the difference between relapsing and progressive MS?
- Relapsing-remitting (RRMS) — clear attacks with recovery — 85% at onset. Secondary progressive — gradual worsening after years of relapses. Primary progressive (PPMS) — steady decline from start without distinct relapses — harder to treat, ocrelizumab approved.
- Does MS affect life expectancy?
- Slightly reduced on average — gap narrowing with modern DMTs — most live near-normal lifespan. Complications — mobility impairment, infections. Quality of life highly variable — many remain working with support and treatment.